Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 156
- Registration Number
- NCT04809311
- Locations
- 🇩🇰
Digital/virtual site, Copenhegan, Denmark
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo insulin icodecDrug: Placebo insulin degludec
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 588
- Registration Number
- NCT04795531
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
🇺🇸Lakeview Clinical Research, LLC, Guntersville, Alabama, United States
🇺🇸American Clinical Trials, Buena Park, California, United States
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 529
- Registration Number
- NCT04788511
- Locations
- 🇨🇿
Nemocnice Jihlava Kardiologie, Jihlava, Czechia
🇭🇺Szent Margit Rendelőintézet Nonprofit Kft., Budapest, Hungary
🇭🇺Semmelweis Egyetem Szent Rókus Klinikai Tömb, Budapest, Hungary
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
- Conditions
- Early Alzheimer´s Disease
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1840
- Registration Number
- NCT04777409
- Locations
- 🇵🇱
Osrodek Alzheimerowski Sp. z o.o., Scinawa, Poland
🇵🇱Centrum Medyczne SENIOR, Sopot, Poland
🇵🇱Centrum Medyczne Neuro Protect, Warszawa, Poland
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
- Conditions
- Early Alzheimer's Disease
- Interventions
- Drug: SemagludtideDrug: Placebo (semaglutide)
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1840
- Registration Number
- NCT04777396
- Locations
- 🇦🇷
FLENI, Caba, Argentina
🇦🇷Instituto Privado Kremer, Córdoba, Argentina
🇦🇷Fundación Scherbovsky, Mendoza, Argentina
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT04775082
- Locations
- 🇵🇹
Hospital Da Luz S.A., Lisboa, Portugal
🇵🇹Unidade Local De Saude De Santa Maria E.P.E., Lisboa, Portugal
🇵🇹Hospital CUF Porto S.A., Porto, Portugal
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 526
- Registration Number
- NCT04770532
- Locations
- 🇯🇵
Futata Tetsuhiro Clinic Meinohama, Fukuoka-shi, Fukuoka, Japan
🇯🇵Naka Kinen Clinic, Ibaraki, Japan
🇯🇵Yuri Ono Clinic, Sapporo-shi, Hokkaido, Japan
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin Glargine 100U/mLDrug: Insulin Glargine 300U/mL
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1085
- Registration Number
- NCT04760626
- Locations
- 🇺🇸
Cedar-Crosse Research Center, Chicago, Illinois, United States
🇬🇷Iatriko Psychicou Private Clinic, Athens, Greece
🇬🇷Korgiallenio - Benakio Hospital (Red Cross Hosp.), Athens, Greece
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: Placebo (NNC0194-0499 )
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT04722653
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1606
- Registration Number
- NCT04707469
- Locations
- 🇺🇸
Elite Clinical Trials, Blackfoot, Idaho, United States
🇺🇸Solaris Clinical Research, Meridian, Idaho, United States
🇺🇸Cedar-Crosse Research Center, Chicago, Illinois, United States